Helix BioPharma Corp. Announces Engagement of Independent Trading Group to Provide Market-Making Services

(TheNewswire)

April 3, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, announces that, subject to regulatory approval, it hasengaged the services of Independent Trading Group ( "ITG" ) toprovide market-making services in accordance with Toronto StockExchange ( “TSX” ) policies. ITG will trade shares ofthe Company on the TSX and all other trading venues with the objectiveof maintaining a reasonable market and improving the liquidity of theCompany's common shares.

Under the agreement, ITG will receive a monthlycompensation, payable in advance. The agreement is for an initial termof one month and will renew for additional one-month terms unlessterminated. The agreement may be terminated by either party with 30days' notice. There are no performance factors contained in theagreement and ITG will not receive shares or options as compensation.ITG and the Company are unrelated and unaffiliated entities and at thetime of the agreement, neither ITG nor its principals have aninterest, directly or indirectly, in the securities of theCompany .

About Independent TradingGroup

Independent Trading Group (ITG) Inc. is a Toronto basedCIRO dealer-member that specializes in market making, liquidityprovision, agency execution, ultra-low latency connectivity, andbespoke algorithmic trading solutions. Established in 1992, with afocus on market structure, execution and trading, ITG has leveragedits own proprietary technology to deliver high quality liquidityprovision and execution services to a broad array of public issuersand institutional investors.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a nearfuture where today’s hard-to-treat cancers are made vincible bynovel therapies that rise to the challenge. The Company innovates fromstrength to tackle cancer’s biggest, most urgent challenges with adiverse pipeline of drug candidates with great potential and a headstart, honed into first- and best-in-class oncology medicines. Itspipeline is spearheaded by a clinical-stage proprietary technologyplatform of bio-conjugates that score with precision against prevalentCEACAM6-expressing solid tumors. Its lead candidate, Tumour DefenceBreaker™ L-DOS47, is a clinical-stage antibody-enzyme conjugate(AEC) that neutralizes the microenvironment of common, hard-to-treatsolid tumors, taking the brakes off anti-cancer immunity anddelivering a game-changing assist to today’s front-runninganti-cancer therapies. L-DOS47 has completed Phase Ib studies innon-small cell lung cancer (NSCLC), with novel strategically designedbi-specific ADCs targeting CEACAM6 in discovery.

Helix is listed on the TSX under the symbol “HBP”,on OTC PINK under the symbol “HBPCD” and on FWB under the symbol“HBP0”. For more information, please visit : https://www.helixbiopharma.com/

For more information, pleasecontact:

Helix BioPharma Corp.

Bay Adelaide Centre - North Tower

40 Temperance Street, Suite 2

Toronto, ON M5H 0B4

Tel: +1 857 208 7687

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risksand Uncertainties

This news release containsforward-looking statements and information (collectively,“forward-looking statements”) within the meaning of applicableCanadian securities laws. Forward-looking statements are statementsand information that are not historical facts but instead includefinancial projections and estimates, statements regarding plans,goals, objectives, intentions and expectations with respect to theCompany’s future business, operations, research and development,including the Company’s activities relating to L-DOS47.Forward-looking statements can further be identified by the use offorward-looking terminology such as “ongoing”, “estimates”,“expects”, or the negative thereof or any other variations thereonor comparable terminology referring to future events or results, orthat events or conditions “will”, “may”, “could”, or“should” occur or be achieved, or comparable terminology referringto future events or results.

Forward-looking statements arestatements about the future and are inherently uncertain and arenecessarily based upon a number of estimates and assumptions that arealso uncertain. Although the Company believes that the expectationsreflected in such forward-looking statements are reasonable, suchstatements involve risks and uncertainties, and undue reliance shouldnot be placed on such statements. Forward-looking statements,including financial outlooks, are intended to provide informationabout management’s current plans and expectations regarding futureoperations, including without limitation, future financingrequirements, and may not be appropriate for other purposes. Certainmaterial factors, estimates or assumptions have been applied in makingforward-looking statements in this news release.

The Company’s actual results coulddiffer materially from those anticipated in the forward-lookingstatements contained in this news release as a result of numerousknown and unknown risks and uncertainties, including withoutlimitation; the risk that the Company’s assumptions may prove to beincorrect; the risk that additional financing may not be obtainable ina timely manner, or at all, and that clinical trials may not commenceor complete within anticipated timelines or the anticipated budget ormay fail; third party suppliers of necessary services or of drugproduct and other materials may fail to perform or be unwilling orunable to supply the Company, which could cause delay or cancellationof the Company’s research and development activities; necessaryregulatory approvals may not be granted or may be withdrawn; theCompany may not be able to secure necessary strategic partner support;general economic conditions, intellectual property and insurancerisks; changes in business strategy or plans; and other risks anduncertainties referred to elsewhere in this news release, any of whichcould cause actual results to vary materially from current results orthe Company’s anticipated future results. Certain of these risks anduncertainties, and others affecting the Company, are more fullydescribed in the Company’s annual management’s discussion andanalysis for the year ended July 31, 2023 under the heading “Risksand Uncertainties” and Helix’s Annual Information Form, inparticular under the headings “Forward-looking Statements” and“Risk Factors”, and other reports filed under the Company’sprofile on SEDAR at www.sedar.com from time to time. Forward-looking statements and information arebased on the beliefs, assumptions, opinions and expectations ofHelix’s management on the date of this new release, and the Companydoes not assume any obligation to update any forward-looking statement or informationshould those beliefs, assumptions, opinions or expectations, or othercircumstances change, except as required.

Copyright (c) 2025 TheNewswire - All rights reserved.